Last reviewed 2026-04-19 · How we verify

Primary cutaneous T-cell lymphoma

Approved treatments

• Flucorticin
• Aclovate
• Cordran · Aqua Pharms
• Farydak · Secura
• Cutivate · Teva Pharm
• Valchlor · Recordati
  Valchlor works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death.
• Topicort · Taro
• Derma-Smoothe/Fs · Eurofarma
• Targretin · Bausch Health
  Targretin works by binding to the retinoic acid receptor RXR-beta, which helps regulate cell growth and differentiation.
• Cloderm · Legacy Pharma
• Cortone
• Ultravate · Ranbaxy
  Ultravate works by binding to the glucocorticoid receptor, triggering a cascade of anti-inflammatory effects that reduce skin inflammation.
• Diprolene · Merck & Co.
  Diprolene works by binding to the glucocorticoid receptor in the skin, which reduces inflammation and suppresses the immune system.
• Verdeso · Padagis Us
• Betamethasone Valerate · Fougera Pharms Inc
• Decadron · Generic (originally Merck)
• Flonase · GSK (GlaxoSmithKline)
• Farydak · Novartis Pharmaceuticals
• Poteligeo · Kyowa Kirin
  Poteligeo works by binding to the C-C chemokine receptor type 4, which is involved in the migration and proliferation of T-cells.
• Istodax · Celgene
• Poteligeo · Kyowa Kirin Pharmaceutical Development Ltd
• prednison · Wen Zhang
• Nasonex · University of Alberta
• Medrol · Generic (originally Upjohn/Pfizer)
  Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions.
• Betamethasone 17-Benzoate
• Cortef · Generic (originally Merck/Upjohn)
• Istodax · Teva Pharms Usa Inc
  Romidepsin inhibits HDACs, leading to increased acetylation of histones and non-histone proteins, causing cell cycle arrest and apoptosis in cancer cells.
• Rodinolone
• Flixotide · Mundipharma Research Limited
• Fluticason · Creighton University
• Deltasone · Generic (originally Schering)
• Lidex
• Halog · Sun Pharma
• Dermatop · Bausch Health
• Ontak · Eisai
• Ontak · Eisai
  Ontak works by binding to the interleukin-2 receptor on cancer cells, triggering a toxic response that kills the cells.
• Elocon · Merck & Co.
  Elocon works by binding to the progesterone receptor, which reduces inflammation and immune response in the body.
• Psorcon · Pfizer
• Oxsoralen-Ultra · Bausch Health
  Oxsoralen-Ultra works by generating free radicals when exposed to ultraviolet A (UVA) light, which helps to slow down the growth of skin cells and reduce inflammation.
• Cyclocort · Astellas Pharma
• Betametasone
  Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system.
• Zolinza · Merck & Co.
  Zolinza works by blocking the action of histone deacetylase 6, an enzyme that removes acetyl groups from histones, leading to changes in gene expression.
• Mogamulizumab-Kpkc · H. Lee Moffitt Cancer Center and Research Institute
  12.1 Mechanism of Action Mogamulizumab-kpkc is a defucosylated, humanized IgG1 kappa monoclonal antibody that binds to CCR4, a G protein-coupled receptor for CC chemokines that is involved in the trafficking of lymphocytes to various organs. Non-clinical in vitro studies demonstrate mogamulizumab-kpkc binding targets a cell for antibody-dependent cellular cytotoxicity (ADCC) resulting in depletion of the target cells. CCR4 is expressed on the surface of some T-cell malignancies and is expressed on regulatory T-cells (Treg) and a subset of Th2 T-cells.
• Cortisol · University of Zurich
• Prelone · Generic (originally Schering)
• Ontak · The University of Texas Health Science Center at San Antonio
• prednisolon · Hannover Medical School
• Methylprednisolon · Leiden University Medical Center
• MOMETASONE
  12.1 Mechanism of Action Mometasone furoate nasal spray is a corticosteroid demonstrating potent anti-inflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation. In two clinical studies utilizing nasal antigen challenge, mometasone furoate nasal spray decreased some markers of the early- and late-phase allergic response. These observations included decreases (vs. placebo) in histamine and eosinophil cationic protein levels, and reductions (vs. baseline) in eosinophils, neutrophils, and epithelial cell adhesion proteins. The clinical significance of these findings is not known. The effect of mometasone furoate nasal spray on nasal mucosa following 12 months of treatment was examined in 46 patients with allergic rhinitis. There was no evidence of atrophy and there was a marked reduction in intraepithelial eosinophilia and inflammatory cell infiltration (e.g., eosinophils, lymphocytes, monocytes, neutrophils, and plasma cells).

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

• Primary cutaneous T-cell lymphoma patent landscape — cliff calendar, originator estates, attackable patents
• Primary cutaneous T-cell lymphoma treatment landscape brief
• Primary cutaneous T-cell lymphoma treatment updates RSS

Frequently asked questions about Primary cutaneous T-cell lymphoma

Related

• Treatment landscape: Primary cutaneous T-cell lymphoma patent cliff · Primary cutaneous T-cell lymphoma CI report
• Treatment: Flucorticin
• Treatment: Aclovate
• Treatment: Cordran · Aqua Pharms
• Treatment: Farydak · Secura
• Treatment: Cutivate · Teva Pharm
• All diseases: Browse the disease index · Disease landscape hub

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing